Compagnie Lombard Odier SCmA’s Royalty Pharma RPRX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$163K	Hold	2,900	–	–	﹤0.01%	290
2026 Q1	$139K	Hold	2,900	–	–	﹤0.01%	272
2025 Q4	$112K	Hold	2,900	–	–	﹤0.01%	291
2025 Q3	$102K	Hold	2,900	–	–	﹤0.01%	297
2025 Q2	$104K	Hold	2,900	–	–	﹤0.01%	284
2025 Q1	$90.3K	Sell	2,900 -5,800	-67%	-$184K	﹤0.01%	313
2024 Q4	$222K	Sell	8,700 -5,300	-38%	-$141K	﹤0.01%	235
2024 Q3	$396K	Sell	14,000 -3,000	-18%	-$83.1K	0.01%	193
2024 Q2	$448K	Hold	17,000	–	–	0.01%	189
2024 Q1	$516K	Sell	17,000 -3,000	-15%	-$88.4K	0.01%	191
2023 Q4	$562K	Sell	20,000 -5,000	-20%	-$137K	0.01%	210
2023 Q3	$679K	Sell	25,000 -5,000	-17%	-$149K	0.02%	169
2023 Q2	$922K	Sell	30,000 -1,500	-5%	-$50.8K	0.03%	142
2023 Q1	$1.13M	Hold	31,500	–	–	0.03%	153
2022 Q4	$1.25M	Hold	31,500	–	–	0.03%	147
2022 Q3	$1.27M	Sell	31,500 -1,000	-3%	-$42.7K	0.04%	150
2022 Q2	$1.37M	Hold	32,500	–	–	0.03%	138
2022 Q1	$1.27M	Hold	32,500	–	–	0.03%	143
2021 Q4	$1.29M	Sell	32,500 -7,500	-19%	-$291K	0.03%	160
2021 Q3	$1.45M	Buy	+40,000	New	+$1.55M	0.03%	153

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Compagnie Lombard Odier SCmA's RPRX Position: Q2 2026 in Review

Compagnie Lombard Odier SCmA held its Royalty Pharma (RPRX) position steady in Q2 2026 at 2,900 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #290.

Compagnie Lombard Odier SCmA first reported a position in RPRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.45M in Q3 2021. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Compagnie Lombard Odier SCmA held 2,900 shares of Royalty Pharma worth $163K as of Q2 2026.
Compagnie Lombard Odier SCmA left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up ﹤0.01% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #290 holding.
Compagnie Lombard Odier SCmA first reported a position in Royalty Pharma in Q3 2021 and has held it in 20 quarters since.
Compagnie Lombard Odier SCmA's Royalty Pharma position peaked at $1.45M in Q3 2021.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.